Literature DB >> 23052407

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.

C G Stott1, L White, S Wright, D Wilbraham, G W Guy.   

Abstract

PURPOSE: To assess the effect of food on the single-dose bioavailability of delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) spray, an endocannabinoid system modulator, when administered to healthy male subjects.
METHODS: Twelve subjects took part in this fed-fasted cross-over study and received a single dose of THC/CBD spray (4 sprays = 10.8 mg THC + 10 mg CBD) in the fasted then fed state (or vice versa) with a 3-day wash-out period between treatments. Plasma samples were collected at designated time-points for analysis of CBD, THC, and its active metabolite, 11-hydroxy delta-9-tetrahydrocannabinol (11-OH-THC).
RESULTS: Statistically significant increases in the mean area under the curve (AUC) and mean maximum plasma drug concentration (Cmax) were observed in subjects during fed conditions. Mean AUC and Cmax were one to three-fold higher for THC and 11-OH-THC, and five and three-fold higher for CBD respectively during fed conditions. A large inter-subject variability in exposure from the same dose was observed, particularly for THC. The Cmax for THC in fed versus fasted subjects was higher in 7 subjects (4.80-14.91 ng/ml) and lower in 5 subjects (2.81-3.51 ng/ml) compared with the mean Cmax of 3.98 ng/ml (range 0.97-9.34 ng/ml) observed in the fasted state. Increases in mean AUC(0-t), AUC(0-inf), and Cmax for THC, CBD, and 11-OH-THC in the fed state were within the range of inter-subject variability, which was considerable. Food also appeared to delay the time to peak concentration (Tmax) of all analytes by approximately 2-2.5 h. Only mild adverse events were reported.
CONCLUSIONS: The THC/CBD spray was well tolerated in male subjects at a single dose of four sprays. The large inter-subject variability in exposure suggests that the changes observed are unlikely to be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052407     DOI: 10.1007/s00228-012-1393-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins.

Authors:  Pavel Gershkovich; Amnon Hoffman
Journal:  Eur J Pharm Sci       Date:  2007-05-18       Impact factor: 4.384

2.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

Authors:  A Lindholm; S Henricsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

3.  A reliable method for the detection, confirmation, and quantitation of cannabinoids in blood.

Authors:  C R Goodall; B J Basteyns
Journal:  J Anal Toxicol       Date:  1995-10       Impact factor: 3.367

Review 4.  International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Authors:  A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

Review 5.  Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH.

Authors:  W N Charman; C J Porter; S Mithani; J B Dressman
Journal:  J Pharm Sci       Date:  1997-03       Impact factor: 3.534

6.  Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

Authors:  Russell K Portenoy; Elena Doina Ganae-Motan; Silvia Allende; Ronald Yanagihara; Lauren Shaiova; Sharon Weinstein; Robert McQuade; Stephen Wright; Marie T Fallon
Journal:  J Pain       Date:  2012-04-05       Impact factor: 5.820

Review 7.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

8.  Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS.

Authors:  P M Kemp; I K Abukhalaf; J E Manno; B R Manno; D D Alford; G A Abusada
Journal:  J Anal Toxicol       Date:  1995-09       Impact factor: 3.367

9.  Quantitative measurement of delta 9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry.

Authors:  R L Foltz; K M McGinnis; D M Chinn
Journal:  Biomed Mass Spectrom       Date:  1983-05
  9 in total
  19 in total

1.  Human Pharmacokinetic Parameters of Orally Administered Δ9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences.

Authors:  Stephanie Lunn; Patrick Diaz; Shannon O'Hearn; Shaina P Cahill; Alexia Blake; Kelly Narine; Jason R B Dyck
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

Review 2.  Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.

Authors:  Uwe K Zettl; Paulus Rommer; Petra Hipp; Robert Patejdl
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

Review 3.  Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Authors:  Yahiya Y Syed; Kate McKeage; Lesley J Scott
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 4.  Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 5.  The Essential Medicinal Chemistry of Cannabidiol (CBD).

Authors:  Kathryn M Nelson; Jonathan Bisson; Gurpreet Singh; James G Graham; Shao-Nong Chen; J Brent Friesen; Jayme L Dahlin; Matthias Niemitz; Michael A Walters; Guido F Pauli
Journal:  J Med Chem       Date:  2020-09-10       Impact factor: 7.446

6.  Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure.

Authors:  Brett C Ginsburg; Lenka Hruba; Armia Zaki; Martin A Javors; Lance R McMahon
Journal:  Drug Alcohol Depend       Date:  2014-03-19       Impact factor: 4.492

7.  A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain.

Authors:  Chris D Verrico; Shonda Wesson; Vanaja Konduri; Colby J Hofferek; Jonathan Vazquez-Perez; Emek Blair; Kenneth Dunner; Pedram Salimpour; William K Decker; Matthew M Halpert
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

8.  Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.

Authors:  Amir I A Ahmed; Geke A H van den Elsen; Angela Colbers; Cornelis Kramers; David M Burger; Marjolein A van der Marck; Marcel G M Olde Rikkert
Journal:  Psychopharmacology (Berl)       Date:  2015-03-11       Impact factor: 4.530

9.  A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.

Authors:  Sophie A Millar; Nicole L Stone; Andrew S Yates; Saoirse E O'Sullivan
Journal:  Front Pharmacol       Date:  2018-11-26       Impact factor: 5.810

Review 10.  Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

Authors:  Emilio Perucca
Journal:  J Epilepsy Res       Date:  2017-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.